Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is positioning itself for revenue growth and expanded market adoption through collaborations in the pharmaco-epigenetics space, particularly with major diagnostic and pharmaceutical companies. The successful validation of the Nu.Q Lung Cancer Test represents a significant milestone that could enhance the attractiveness of its technology for strategic partnerships. Additionally, the adoption of its Nu.Q Discover biomarkers by over 1,000 veterinary hospitals in Japan highlights strong market demand and underscores the company's capacity to increase revenue through innovation and automation in diagnostics.

Bears say

VolitionRX Ltd is engaged in developing blood tests utilizing its Nucleosomics platform, which aims to improve disease diagnosis and monitoring, particularly in the context of cancers and NETosis-related conditions. The company is currently facing challenges, as indicated by its study focusing on reducing false-positive rates in pulmonary nodule differentiation—an area plagued by issues leading to unnecessary invasive procedures. These challenges highlight potential limitations in the efficacy and reliability of its diagnostic tests, raising concerns about the company’s market competitiveness and overall financial performance.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.